The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Living With HIV: Watch Aaron's Story
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary


U.S. FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

June 18, 2014

This article was reported by TechTimes.

TechTimes reported that the U.S. Food and Drug Administration (FDA) has granted priority review for Illinois-based drug manufacturer AbbVie's experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug's application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. FDA first granted breakthrough therapy designation to the manufacturer's investigational treatment for chronic genotype 1 HCV in May 2013 when preliminary clinical evidence showed that the regimen led to better results than conventionally accepted treatments. AbbVie's new regimen consists of an antiviral called

View Full Article

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: